JP2017529851A - 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター - Google Patents

養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター Download PDF

Info

Publication number
JP2017529851A
JP2017529851A JP2017516350A JP2017516350A JP2017529851A JP 2017529851 A JP2017529851 A JP 2017529851A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017529851 A JP2017529851 A JP 2017529851A
Authority
JP
Japan
Prior art keywords
cell
cells
seq
gpc3
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529851A5 (OSRAM
Inventor
ヘクジー、アンドラス
ゴットシャルク、ステファン、エム．ジー．
メテリツァ、レオニド、エス．
ドッティ、ジャンピエトロ
リー、ウェンポン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2017529851A publication Critical patent/JP2017529851A/ja
Publication of JP2017529851A5 publication Critical patent/JP2017529851A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
JP2017516350A 2014-09-26 2015-09-25 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター Pending JP2017529851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055979P 2014-09-26 2014-09-26
US62/055,979 2014-09-26
PCT/US2015/052227 WO2016049459A1 (en) 2014-09-26 2015-09-25 Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy

Publications (2)

Publication Number Publication Date
JP2017529851A true JP2017529851A (ja) 2017-10-12
JP2017529851A5 JP2017529851A5 (OSRAM) 2018-11-08

Family

ID=55582053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516350A Pending JP2017529851A (ja) 2014-09-26 2015-09-25 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター

Country Status (6)

Country Link
US (1) US20170281683A1 (OSRAM)
EP (2) EP3198010B1 (OSRAM)
JP (1) JP2017529851A (OSRAM)
DE (1) DE20196219T1 (OSRAM)
ES (2) ES2844700T3 (OSRAM)
WO (1) WO2016049459A1 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021186397A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car-t cell compositions and methods of making and using the same
WO2021186395A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car- t cells secreting il-18 and methods of making and using the same
JP2021534740A (ja) * 2018-08-14 2021-12-16 ソティオ，リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
JP2023549939A (ja) * 2020-12-14 2023-11-29 北京基因▲啓▼明生物科技有限公司 高い増幅、生存能力及び殺腫瘍作用を有するＣＡＲ－ｉＮＫＴ及びその使用
JP2024045239A (ja) * 2018-12-19 2024-04-02 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キメラ抗原受容体を発現する粘膜関連インバリアントｔ（ｍａｉｔ）細胞

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018067696A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag membros de ligação à pd-l1
JP7145761B2 (ja) * 2016-04-22 2022-10-03 クレイジュ・メディカル・カンパニー・リミテッド 細胞免疫療法の組成物および方法
SG11201900634VA (en) 2016-07-26 2019-02-27 Tessa Therapeutics Pte Ltd Chimeric antigen receptor
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
JP2018093823A (ja) * 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
IL300270A (en) 2017-01-10 2023-04-01 Univ Yamaguchi Anti-GPC3 antibody
MX420947B (es) * 2017-04-26 2025-02-10 Eureka Therapeutics Inc Constructos que reconocen específicamente glipicano 3 y usos de estos.
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
SG11202011751WA (en) 2018-06-22 2021-01-28 Kite Pharma Inc Chimeric transmembrane proteins and uses thereof
US20210261646A1 (en) * 2018-07-03 2021-08-26 Sotio, LLC Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
EP3825404A4 (en) * 2018-07-17 2022-04-13 Noile-Immune Biotech, Inc. SINGLE-CHAIN ANTI-GPC3 ANTIBODY WITH CAR
KR20210087458A (ko) 2018-10-01 2021-07-12 아디셋 바이오, 인크. 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
AU2019374828A1 (en) * 2018-11-07 2021-05-27 Sotio, LLC Anti-GPC3 chimeric antigen receptors (CARs) in combination with trans co-stimulatory molecules and therapeutic uses thereof
EP3894011B1 (en) 2018-12-11 2025-09-17 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
EP3964568A4 (en) * 2019-04-04 2023-01-11 Shanghai Pharmaceuticals Holding Co., Ltd. IMMUNE CELL CONTAINING A TUMOR ANTIGEN RECOGNITION RECEPTOR AND THEIR APPLICATION
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
MX2021015451A (es) 2019-06-21 2022-02-11 Kite Pharma Inc RECEPTORES DE TGF-ß Y MÉTODOS DE USO.
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US20240181055A1 (en) 2021-04-08 2024-06-06 Crage Medical Co., Limited Cellular immunotherapy use
CN118488969A (zh) 2021-11-16 2024-08-13 舒迪安生物技术公司 粘液样/圆形细胞脂肪肉瘤患者的治疗
CN116555414A (zh) * 2023-04-03 2023-08-08 上海交通大学医学院附属瑞金医院 Gpc3和gpc3 car-t在诊断、治疗特发性肺纤维化中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN103483453A (zh) * 2012-06-12 2014-01-01 上海吴孟超医学科技基金会 结合egfr家族蛋白的嵌合抗原受体、其组合物及用途
US20140044714A1 (en) * 2011-04-19 2014-02-13 Mitchell Ho Human monoclonal antibodies specific for glypican-3 and use thereof
WO2014138314A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP7510246B2 (ja) 2015-08-03 2024-07-03 クレージュ メディカル カンパニー，リミテッド 抗グリピカン３抗体およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044714A1 (en) * 2011-04-19 2014-02-13 Mitchell Ho Human monoclonal antibodies specific for glypican-3 and use thereof
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN103483453A (zh) * 2012-06-12 2014-01-01 上海吴孟超医学科技基金会 结合egfr家族蛋白的嵌合抗原受体、其组合物及用途
WO2014138314A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUM. PATHOL., 2012, VOL.43, NO.5, P.695-701, JPN6019027704, ISSN: 0004077702 *
J. PEDIATR. HEMATOL. ONCOL., 2001, VOL.23, NO.8, P.496-499, JPN6019027708, ISSN: 0004077701 *
PEDIATR. DEV. PATHOL., 2013, VOL.16, P.272-277, JPN6019027710, ISSN: 0004077703 *
日本分子腫瘍マーカー研究会誌, 2010, VOL.25, P.31-32, JPN6019027706, ISSN: 0004077704 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534740A (ja) * 2018-08-14 2021-12-16 ソティオ，リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
JP7456638B2 (ja) 2018-08-14 2024-03-27 ソティオ，リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
JP2024045239A (ja) * 2018-12-19 2024-04-02 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キメラ抗原受容体を発現する粘膜関連インバリアントｔ（ｍａｉｔ）細胞
WO2021186397A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car-t cell compositions and methods of making and using the same
WO2021186395A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car- t cells secreting il-18 and methods of making and using the same
JP2023518931A (ja) * 2020-03-18 2023-05-09 ユーティレックス カンパニー リミテッド Ｉｌ－１８を分泌するｇｐｃ３ ｃａｒ－ｔ細胞、並びにそれを作製する方法及び使用する方法
JP2023518930A (ja) * 2020-03-18 2023-05-09 ユーティレックス カンパニー リミテッド Ｇｐｃ３ ｃａｒ－ｔ細胞組成物、並びにそれを作製する方法及び使用する方法
JP7778081B2 (ja) 2020-03-18 2025-12-01 ユーティレックス カンパニー リミテッド Ｉｌ－１８を分泌するｇｐｃ３ ｃａｒ－ｔ細胞、並びにそれを作製する方法及び使用する方法
JP2023549939A (ja) * 2020-12-14 2023-11-29 北京基因▲啓▼明生物科技有限公司 高い増幅、生存能力及び殺腫瘍作用を有するＣＡＲ－ｉＮＫＴ及びその使用
JP7638025B2 (ja) 2020-12-14 2025-03-03 北京基因▲啓▼明生物科技有限公司 高い増幅、生存能力及び殺腫瘍作用を有するＣＡＲ－ｉＮＫＴ及びその使用

Also Published As

Publication number Publication date
WO2016049459A1 (en) 2016-03-31
EP3198010A4 (en) 2018-06-06
EP3198010B1 (en) 2020-11-04
ES2851123T1 (es) 2021-09-03
EP3858991A1 (en) 2021-08-04
DE20196219T1 (de) 2021-10-28
ES2844700T3 (es) 2021-07-22
EP3198010A1 (en) 2017-08-02
US20170281683A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
EP3198010B1 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
US11725061B2 (en) CSGP4—specific chimeric antigen receptor for cancer
US20220125847A1 (en) Universal immune cells for cancer immunotherapy
US20250011462A1 (en) Method of treating a tumor expressing carbonic anhydrase ix (g250) by administering a g250-specific chimeric antigen receptor
JP6678215B2 (ja) がんにおけるｃｄ１３８の標的化
JP7107579B2 (ja) 細胞治療のための構造的に活性なサイトカイン受容体
ES2681948T3 (es) Células de acoplamiento para inmunoterapia
US11649284B2 (en) Cancer gene therapy targeting CD47
JP7233720B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP2018504894A (ja) キメラ抗原受容体およびその使用方法
JP2016513458A (ja) 化学療法耐性免疫細胞
BR112019019941B1 (pt) Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método
JP2023504560A (ja) ｃ－Ｋｉｔ変異を発現する細胞およびその使用
AU2018367449A1 (en) IL-33 secreting immunoresponsive cells and uses thereof
HK40056951A (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
CA3167014A1 (en) Novel dominant negative fas polypeptides, cells comprising thereof and uses thereof
HK1239732B (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
HK1239732A1 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
WO2023081878A2 (en) Engineered immune cells and methods for use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200401